key: cord-0856613-t3cmgk46
authors: Mosharaf, Md. Parvez; Reza, Md. Selim; Kibria, Md. Kaderi; Ahmed, Fee Faysal; Kabir, Md. Hadiul; Hasan, Sohel; Mollah, Md. Nurul Haque
title: Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing
date: 2022-03-11
journal: Sci Rep
DOI: 10.1038/s41598-022-08073-8
sha: 19cd7e5c157d3fbf66997c7fe24805ded40d88cc
doc_id: 856613
cord_uid: t3cmgk46

The pandemic threat of COVID-19 has severely destroyed human life as well as the economy around the world. Although, the vaccination has reduced the outspread, but people are still suffering due to the unstable RNA sequence patterns of SARS-CoV-2 which demands supplementary drugs. To explore novel drug target proteins, in this study, a transcriptomics RNA-Seq data generated from SARS-CoV-2 infection and control samples were analyzed. We identified 109 differentially expressed genes (DEGs) that were utilized to identify 10 hub-genes/proteins (TLR2, USP53, GUCY1A2, SNRPD2, NEDD9, IGF2, CXCL2, KLF6, PAG1 and ZFP36) by the protein–protein interaction (PPI) network analysis. The GO functional and KEGG pathway enrichment analyses of hub-DEGs revealed some important functions and signaling pathways that are significantly associated with SARS-CoV-2 infections. The interaction network analysis identified 5 TFs proteins and 6 miRNAs as the key regulators of hub-DEGs. Considering 10 hub-proteins and 5 key TFs-proteins as drug target receptors, we performed their docking analysis with the SARS-CoV-2 3CL protease-guided top listed 90 FDA approved drugs. We found Torin-2, Rapamycin, Radotinib, Ivermectin, Thiostrepton, Tacrolimus and Daclatasvir as the top ranked seven candidate drugs. We investigated their resistance performance against the already published COVID-19 causing top-ranked 11 independent and 8 protonated receptor proteins by molecular docking analysis and found their strong binding affinities, which indicates that the proposed drugs are effective against the state-of-the-arts alternatives independent receptor proteins also. Finally, we investigated the stability of top three drugs (Torin-2, Rapamycin and Radotinib) by using 100 ns MD-based MM-PBSA simulations with the two top-ranked proposed receptors (TLR2, USP53) and independent receptors (IRF7, STAT1), and observed their stable performance. Therefore, the proposed drugs might play a vital role for the treatment against different variants of SARS-CoV-2 infections.

Identification of differentially expressed genes (DEGs). We www.nature.com/scientificreports/ at adjusted p-value < 0.05 and the fold change threshold |log 2 (aFC g )|> 1 by controlling the FDR at 5%. We separated upregulated and downregulated DEGs by using fold change criteria log 2 (aFC g ) > 1 and log 2 (aFC g ) < − 1 respectively. However, we observed that a set of 2 DEGs denoted by C = {ZNF638-IT1, FOSB} showed contradictory results by edgeR and DESeq2. So, we removed these 2 DEGs from further analysis. Finally, we considered the set of 107 Table 2) . To visualize sample clusters (case/control) and outliers simultaneously based on DEGs, we constructed the scatter plot of first and second principal components (PCs) of DEGs (Fig. 2d) . We observed control samples are clearly separated from the case samples. So, the DEGs-set has a strong prognosis power. We also observed that 6 samples were contaminated by outliers (indicated with round line). www.nature.com/scientificreports/ Protein-protein interaction (PPI) network analysis of DEGs. The PPI network of DEGs was constructed to detect the most representative DEGs so called hub-DEGs/proteins (see Fig. 3 ). A topological exploration based on dual-metric measurements (degree (> 10) and betweenness) was utilized to select the top-ranked 10 hub-DEGs/proteins that are SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1, GUCY1A2 and CXCL2, where 2 hub-DEGs (IGF2 and SNRPD2) were upregulated and the remaining 8 were found as downregulated (see Table 2 ). These hub-DEGs/proteins were considered as the key controller of SARS-CoV-2 infections and drug target receptors. CD79B, ITM2C, METTL24, PPP1R1A, RNU1-28P, RNU1-3,  RP11-488L18.8, ATPIF1, FOLR2, H19, ICAM2, IGF2, NDUFA8,  PLVAP, SNRPD2   AC007278.2, AC007278.3, AC009303.1, AC068580.6, ACER3,  AP001189.4, ARL5B, BEST1, CCL18, CCL20, CD300E, CTB89H12.4,  CTD2537I9.18, CXCL2, CYP1B1, CYR61, DESI2, DGKH, DUSP6,  EDN1, ENPP4, ERAP2, GAPDHP59, GK, GLDN, GUCY1A2,  HS3ST2,IGFN1, IGSF10, KLF6, LRRTM2, MTND1P23, NAMPTP1,  NAV2-AS4, NAV2-AS5, NCR3LG1, NEDD9, NLRP3, NUPL1, NUS1,  OGFRL1, OSBPL8, PAG1, PTP4A1, PZP, RASGEF1B, RNU2-61P, RP1- Table 3 and Supplementary File S1). The Table 3 shows top 10 significantly enriched GO-terms for each of three categories (MFs, BPs and CCs). We observed that 3 MFs (protein binding, binding, molecular function) were significantly enriched with all 10 hub-DEGs, 1 MF (protein-containing complex binding) was enriched with 3 hub-DEGs (IGF2, TLR2, GUCY1A2), 1 MF (C-C chemokine binding) was enriched with ZFP36 hub-DEG and the rest 5 MFs (triacyl lipopeptide binding, lipopolysaccharide immune receptor activity, lipopeptide binding, NAD+ nucleotidase, cyclic ADPribose generating and NAD+ nucleosidase activity) were significantly enriched with TLR2. Out of top 10 significantly enriched GO-terms of BPs by hub-DEGs, we observed that 2 BPs (biological process and cellular process) were highly enriched by all of 10 hub-DEGs, 5 BPs, (biological regulation, response to stimulus, positive regulation of cellular process, signal transduction and immune system process) were enriched by the individual sub DEGs-sets including 9, 8, 7, 7 and 6 hub-DEGs, respectively. The other 3 GO-terms (cellular response to lipopolysaccharide, cellular response to molecule of bacterial origin and cellular response to biotic stimulus) of BPs were enriched by the same 3 hub-DEGs (ZFP36, TLR2, CXCL2). Among the top 10 significantly enriched GO-terms of CCs by hub-DEGs, 2 CCs (cellular component and cellular anatomical entity) were enriched by all 10 hub-DEGS, 7 hub-DEGs significantly enriched with the cytoplasm of CCs, 2 hub-DEGs (TLR2 and PAG1) significantly enriched with 3 GO-terms membrane raft, membrane microdomain and membrane region of CCs and the rest 4 CCs (Dcp1-Dcp2 complex, Toll-like receptor 1-Toll-like receptor 2 protein complex, pICln-Sm protein complex and RISC-loading complex) were enriched by ZFP36, TLR2, SNRPD2 and ZFP36, respectively. :0005515 0.0000  10  SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1,  GUCY1A2, CXCL2   Binding  GO:0005488 0.0001  10  SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1,  GUCY1A2, CXCL2   Molecular function  GO:0003674 0.0002  10  SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1,  GUCY1A2, www.nature.com/scientificreports/ The KEGG pathway enrichment analysis exposed that our proposed hub-DEGs are significantly enriched with plentiful pathway categories (see Fig. 4 and Supplementary File S1). The Fig. 4 showed the top 10 significantly enriched KEGG-pathway categories. We observed that the KEGG root term is significantly enriched with 7 hub-DEGs (SNRPD2, ZFP36, IGF2, TLR2, GUCY1A2, and CXCL2). Each of three pathway categories legionellosis, amoebiasis and rheumatoid arthritis was enriched by two hub-DEGs (TLR2 and CXCL2). Each of two pathway categories (proteoglycans in cancer and PI3K-Akt signaling) was enriched by two hub-DEGs (TLR2 and IGF2). The pathway category Kaposi sarcoma-associated herpesvirus infection was enriched by two hub-DEGs (ZFP36 and CXCL2). The two KEGG pathway categories (long-term depression and renin secretion) was enriched by the hub-DEG GUCY1A2. The rest one pathway category IL-17 signaling pathway was enriched by the hub-DEG CXCL2.

The gene regulatory network (GRN) analysis of hub-DEGs. Transcription factors (TFs) and micro-RNAs (miRNAs) are considered as the most important transcriptional and post transcriptional molecular regulatory factors of genes. We constructed undirected interaction network between TFs and hub-DEGs to explore key regulatory transcriptional factors of hub-DEGs (Fig. 5) . In this network, hub-DEGs were represented by round nodes with red color and TFs were represented by square nodes with blue color, where larger numbers of connectivity were represented by the larger nodes. We selected FOXC1, GATA2, SRF, FOXL1, YY1 and NFIC as the top 6 key regulatory TFs of hub-DEGs based on higher degree of topological measures.

To explore key regulatory post-transcriptional factors of hub-DEGs, we constructed undirected interaction network between miRNAs and hub-DEGs (Fig. 6) . In this network, hub-DEGs were represented by round nodes with red color and miRNAs were represented by octagonal nodes with green color, where larger numbers of Table S2 show the disease versus hub-DEGs interaction network analysis results. We observed that IGF2 gene is associated with 120 diseases including Cardiovascular Diseases, Colorectal Neoplasms, Cardiomyopathies, Liver carcinoma, Anemia; the CXCL2 gene is associated with 19 diseases including rheumatoid arthritis, heart failure, hypertensive disease, IBN inflammation, pulmonary fibrosis, acute lung injury while the ZFP36, KLF6, GUCY1A2 and PAG1 was linked with 18 diseases including liver cirrhosis, experimental prostatic neoplasms, stomach carcinoma, inflammation, arthritis, especially which could be a severe comorbidities of the COVID-19 patients. To assess the association of hub-DEGs with lung cancer, we performed multivariate survival analysis of lung cancer patients with expressions of hub-DEGs. The log-rank test was used to test the significant difference between two survivals curves (Fig. 7b ) based on all hub-DEGs. We observed the significant difference between the low and high-risk group in survival probability, which indicates that the hub proteins are significantly associated with lung cancer.

Drug repurposing by molecular docking study. We considered 10 hub-proteins corresponding to our proposed 10 hub-DEGs and their regulatory 5 key TFs-proteins (FOXC1, GATA2, SRF, FOXL1 and YY1) as the m = 15 drug target receptors. The SARS-CoV-2 3CL protease-guided top-ranked n = 90 drugs out of 3410 FDA approved antiviral drugs 50 , were considered as the drug agents that were mentioned previously in the materials and method section. We downloaded 3D structure of 7 hub proteins (SNRPD2, ZFP36, NEDD9, IGF2, TLR2, and CXCL2) from Protein Data Bank (PDB) 51 with source codes 5xjs, 4j8s, 2l81, 1igl, 1fyw, and 5ob5, respectively. The 3D structure of 3 hub proteins (KLF6, USP53, GUCY1A2, and PAG1) were downloaded from SWISS-MODEL 52 using UniProt 53 ID of Q99612, Q70EK8, P33402, and Q9NWQ8, respectively. The 3D structure of 3 TFs proteins (GATA2, SRF and YY1) were downloaded from PDB with source codes 5o9b, 1hbx, and 1ubd, respectively, and the rest 2 TFs proteins (FOXC1 and FOXL1) were downloaded from SWISS-MODEL using UniProt ID of Q12948 and Q12952. The 3D structures of 90 FDA-approved drugs were downloaded from PubChem database 54 . Then we performed molecular docking study to calculate binding affinity scores for each pair of receptors and drug agents. Then we ordered the receptor proteins according to the descending order of row sums of the binding affinity score matrix A = (A ij ) and drug agents according to the column sums to select the top-ranked few drug agents as the candidate drugs. Figure 8a displayed the image of binding affinity matrix A * = A * ij corresponding to the ordered target proteins in Y-axis and top-ordered 50 drug agents out of 90 in www.nature.com/scientificreports/ X-axis. We observed that the first two top lead compounds (lead1: Torin-2 and lead2: Rapamycin) produce binding affinity scores less than or equal to − 8.0 kcal/mol with all of our proposed 15 receptor proteins. The next (3-7)th top lead compounds (lead3:Radotinib, lead4:Ivermectin, lead5:Thiostrepton, lead6:Tacrolimus and lead7:Daclatasvi) produced binding affinity scores less than or equal to − 8.0 kcal/mol with our proposed 13 receptor proteins out of 15. The rest 83 lead compounds produced binding affinity scores less than or equal to − 8.0 kcal/mol with the fewer number of receptors. Therefore, we considered the top 7 lead compounds (Torin-2, Rapamycin, Radotinib, Ivermectin, Thiostrepton, Tacrolimus and Daclatasvi) as the most probable candidate drugs for SARS-CoV-2 infections. To validate our proposed 7 candidate drugs by molecular docking study with already published independent receptor proteins (genomic biomarkers) associated with SARS-CoV-2 infections available in the literature, we reviewed 22 published articles associated with SARS-CoV-2 infections those provided transcriptome guided hubproteins (genomic biomarkers). We found total of 193 hub-proteins published in those 22 articles, but there was no hub-protein commonly published in all articles (Table 4) . We found 11 hub-proteins (ICAM1, IRF7, MX1, NFKBIA, STAT1, IL6, TNF, CCL20, CXCL8, VEGFA, and CASP3) which were commonly reported in at most 3 articles out of 22 (Table 4 ). We considered these 11 hub-proteins as the publicly available top ranked receptor proteins associated with SARS-CoV-2 infections to validate the proposed repurposed drugs by molecular docking. The 3D structures of these 11 (ICAM1, IRF7, MX1, NFKBIA, STAT1, IL6, TNF, CCL20, CXCL8, VEGFA, and CASP3) proteins were retrieved from Protein Data Bank (PDB) with codes 5mza, 2o61, 3szr, 1nfi, 1bf5, 1il6, 1tnf, 2jyo, 1ikl, 1cz8, and 1gfw, respectively. Then molecular docking interactions of our proposed drugs with the publicly available top ranked receptor proteins were performed. Their binding affinities (kcal/mol) were visualized in Fig. 8b . We observed that their binding affinities ranged between (− 12.1 to − 7) kcal/mol and average binding affinities were less than or equal to − 9.5 kcal/mol which indicates the strong binding capacity. Then we compared the docking results of top-ranked eight receptor proteins (four from the proposed set and the other four from the published set) with their protonation state at their physical conditions of salinity = 0.15, internal dielectric = 10, pH = 7, and external dielectric = 80 (see Supplementary File S4) 55 . The docking analysis showed the significant binding affinities ranged between (− 11 to − 7.7) kcal/mol with the protonated receptors ( Fig. 8c) . We observed that both original and protonated (*) receptors produce almost similar binding scores, which indicate the proposed drugs might be effective against the protonated receptors also. Table 5 , Supplementary Files S3 and S4 show the summary results of interacting properties of our target proteins with top-ranked drugs (lead compounds) that produced the highest binding affinity scores. The 3D structure of their interacting complex is shown in the 4th column of Table 5 . The 2D schematic diagram of these 3 target proteins with mentioned candidate drugs interaction is given in the 5th column highlighting their www.nature.com/scientificreports/ neighbor residues (within 4 Å of the drug). Key interactions amino acids and their binding with potential targets were shown in the last column.

Radotinib were the top ranked three candidate drugs (Table 5) . Therefore, these top three drug agents were selected for their stability analysis through 100 ns MD-based MM-PBSA simulations. Fig. 9 , we observed that all the six systems are significantly stable between the variations of moving and initial drug-target complexes. We calculated their RMSD (root mean square deviation). Figures 9a ,b, represents the RMSD corresponding to the proposed receptors (TLR2, USP53) and independent receptors (IRF7, STAT1), respectively. All the systems projected the RMSD around 2 to 4 Å except USP53_Radotinib complex which showed the RMSD around 3.5 to 6.5 Å. The average RMSD for TLR2_Torin-2, TLR2_Rapamycin and USP53_Radotinib complexes were 3.3 Å, 3.7 Å and 4.7 Å, respectively. TLR2_Torin-2 complex showed slight fluctuation in Cα backbone around 40,000 ps and was stabilized in the remaining simulation. Similarly, a streak of continuous fluctuation was found in the TLR2_Rapamycin complex, ranging from 30,000 to 56,000 ps, followed by inconsiderable change. For USP53_radotinib complex, a negligible fluctuation was observed in the starting 12,000 ps and around 62,000 ps to 80,000 ps and remained stable thereafter throughout the simulation. On the other hand, the average RMSD was found to be 3.3 Å for IRF7_Torin-2 complex with slight fluctuation in Cα backbone around 12,000 to 16,000 ps and was stabilized in the remaining simulation. For STAT1_Rapamycin complex, the average RMSD was found to be 2.9 Å. The average RMSD for the STAT1_radotinib bound complex was 2.4 Å, with an overall RMSD of approximately 2.6 Å, indicating that it was comparably more stable among the six selected systems. However, the data indicates that all the systems showed stable internal motion. 

The current study analyzes the high throughput RNA-Seq data to identify key genomic biomarkers (hub DEGs/ proteins) highlighting their GO terms and KEGG pathways, key regulatory components (TFs and miRNAs), associated comorbidities and repurposable drugs for the treatment against SARS-CoV-2 infections by using the integrated bioinformatics approaches that were summarized in Fig. 1 . Totally 109 DEGs were identified between SARS-CoV-2 infected and control samples; among them 16 upregulated and 91 down regulated genes (Table 2) were finally reported. Among them 107 DEGs encoded proteins were used to construct the PPI network (Fig. 3 ) TP53, HRAS, CTNNB1, FYN, ABL1, STAT3, STAT1,  JAK2, C1QBP, XBP1, BST2, CD99, IFI35, MAPK11,  RELA, LCK, KIT, EGR1, IL20, ILF3, CASP3, IL19 www.nature.com/scientificreports/ www.nature.com/scientificreports/ which revealed ten hub-DEGs/proteins (SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1, GUCY1A2 and CXCL2) which are considered as the key genomic biomarkers for SARS-CoV-2 infections. The GO functional enrichment analysis of the proposed hub-DEGs/proteins and all the DEGs reflected the significant molecular functions that are highly linked with the COVID-19 infection and proliferation in host cell (Table 3 and Supplementary Files S1 and S2). Among the enriched MFs, the lipopolysaccharide (LPS) immune receptor activity driven by TLR2 hub-DEG is associated with the LPS-induced production of pro-inflammatory cytokines reduction, inflammation by affecting the lungs LPS due to the COVID-19 infection [56] [57] [58] . The most important and significant functions namely, cytokine regulation, produces the unnecessary "cytokine storm" that promote the adverse events like alveolar damage and fibrosis 59,60 on COVID-19 patients. The interleukin (IL) regulatory pathways are crucial for the important pathophysiological mechanisms called systemic inflammation and cytokine release syndrome [61] [62] [63] which were significantly associated with the hub genes (Supplementary File S1). The C-C chemokine binding functions driven by ZFP36 hub-DEG are directly involved with the T-cell induced pathogen burden controlling which is also an important receptor group protein for COVID-19 [63] [64] [65] . The NAD + nucleotidase MF (steered by TLR2 hub-DEG) was found to have protective roles, and mitigate the disease severity if administered prophylactically, and its anti-hyper inflammation properties 66, 67 and the Dcp1-Dcp2 complex (steered by ZFP36 hub-DEG) play a positive role in viral infection 68 . The above enrichment analysis noticeably focuses on the association of the identified hub proteins with the diverse significant functions that are crucial for COVID-19. Moreover, the functional enrichment and pathway analysis of all the identified DEGs were recorded, and it was found that the functional pathways enriched by the key DEGs were also enriched by all the DEGs significantly (Supplementary File S1 and S2). The common functional pathways enrichment showed the biological uniformity characteristics among the all identified DEGs and the hub-DEGs.

The KEGG pathway analysis of the proposed hub-DEGs/proteins showed some enriched significant pathways. The top 10 significant KEGG pathways included the legionellosis related pathway, IL-17 signaling pathway, Rheumatoid arthritis pathway, PI3K-Akt signaling pathway, Kaposi's sarcoma-associated herpesvirus infection and the proteoglycans in cancer pathways (Fig. 4) . One of the most important pathways driven by TLR2 and CXCL2 hub-DEG namely, the legionellosis which is a typical pneumonia and exposes the cough, shortness of breath, high fever, muscle pains, and headaches 69 . These symptoms are also highly related and most common symptoms for COVID-19 positive patient 70 . During this pandemic situation, the emergency COVID-19 positive patients were permitted to treat with the Hydroxychloroquine (HCQ) although its molecular mechanisms were not completely known and later on WHO advised to avoid this for the treatment. The HCQ -is also commonly used in rheumatic disease treatment and it has been shown that the patients with rheumatoid arthritis (RA) represent lower risk of COVID-19 infection 64 . In our analysis, the hub-DEGs TLR2 and CXCL2 significantly enriched the rheumatoid arthritis pathway which indicates that these genes may have the antagonized property against the COVID-19 infection. The other significant pathways are Kaposi's sarcoma-associated herpesvirus infection (steered by ZFP36 and CXCL2), PI3K-Akt signaling pathway and the proteoglycans in cancer pathways (steered by IGF2 and TLR2). The Kaposi's sarcoma-associated herpesvirus infection is associated with the lung infection 71 , and the PI3K-Akt signaling pathway mainly works with the cell cycle and also with the various proteins function 72, 73 . On the other hand, the proteoglycans in cancer pathways is treated as an important cancer related pathway in human 74 . Therefore, based on the molecular pathway enrichment analysis, it can be presumed that the proposed hub proteins may have significant roles in SARS-CoV-2 infection and proliferation and may be treated as prominent therapeutic target.

The TFs versus Hub-DEGs interaction network analysis revealed 6 key TFs-proteins (FOXC1, GATA2, SRF, FOXL1, YY1 and NFIC) as the transcriptional regulatory factors of hub-DEGs (Fig. 5) . The basal-like breast cancer (BLBC), Alzheimer's disease, tissue invasion are highly associated with the FOXC1 protein 75, 76 . The GATA2 protein is associated with breast and kidney cancer related pathway, when the higher expression pattern of YY1 protein increases the tumour size, higher TNM stage [77] [78] [79] , the FOXL1 TF are related with proliferation, cell-cycle 80 . The SRF protein is associated with the regulation of cell survival and cell cycle progression in cardiac fibroblasts 81 . The NFIC protein has greater involvement with the tumor genesis of breast cancer, gastric cancer, and glioma [82] [83] [84] . Also the identified TFs proteins has a significant involvement in various biological functions and pathways [19] [20] [21] [22] 85 . The miR-107, miR-16-5p, miR-103a-3p, miR-27a-3p, miR-155-5p and miR-1-3p were identified as the key post transcriptional regulatory factors of hub-DEGs (Fig. 6) . The miR-107 (microRNA) has direct interaction with the Coxsackie B3 virus (CVB3) replication and release 86 . The miR-16-5p represented higher expression pattern in lung cancer cell 87 and the miR-103a-3p and miR-27a-3p has a positive correlation with the renal inflammatory dysfunction, cell proliferation and apoptosis 88, 89 while the miR-155-5p is associated with breast cancer 90 and the miR-1-3p has the probable interaction with the SARS-CoV2 91 . The above discussion gives the evidence that the proposed regulatory TFs and the miRNAs have an enormous correlation with various biological functions and processes that are closely connected with the symptoms of SARS-CoV-2 infections and proliferation process.

The diseases versus hub-DEGs interaction network analysis showed that the predicted hub-DEGs are associated with various types of cancers and other complex diseases including the respiratory cases (Fig. 7 , Supplementary Table S2 ). The IGF2 was connected with maximum number of diseases in the network followed by the other hub-DEGs. We observed that IGF2 gene is associated with 120 diseases including Cardiovascular Diseases, Colorectal Neoplasms, Cardiomyopathies, Liver carcinoma, Anemia; the CXCL2 was associated with 19 diseases including Rheumatoid Arthritis, Heart failure, Hypertensive disease, Inflammation, Pulmonary Fibrosis, Acute Lung Injury while the ZFP36, KLF6, GUCY1A2 and PAG1 was linked with 18 diseases including Liver Cirrhosis, Experimental Prostatic Neoplasms, Stomach Carcinoma, Inflammation, Arthritis, especially which could be a severe comorbidities of the COVID-19 patients. Among the associated diseases six diseases were connected with two hub-DEGs, notably, inflammation, mammary neoplasms, myocardial ischemia, colorectal neoplasms, somatic mutation, schizophrenia. The inflammation is considered as vital COVID-19 related comorbidity while www.nature.com/scientificreports/ others are also crucial. The hub-DEGs those are related with the above comorbidities also play a significant role for these diseases during the COVID-19 affection. The association of hub-DEGs with several diseases is also supported by the literature review. For example, the hub-protein SNRPD2 is significantly associated with histologic grade in Hepatocellular carcinoma (HCC), mild cognitive impairment (MCI) and Alzheimer's disease (AD) 92, 93 . The hub-protein ZFP36 is associated with breast cancer and tumor-suppressive actions during hepatic tumor progression 94, 95 . The hub-protein NEDD9 is significantly associated with head and neck and lung cancers 96, 97 . The hub-protein KLF6 has a direct involvement in ovarian cancer cell proliferation and metastasis promotion and also works as a critical regulator of pathogenic myeloid cell activation in human 98, 99 . The USP53 genes has a greater involvement in cholestatic liver disease 100,101 and the IGF2 proteins are widely known as the diabetes associated protein and can control the insulin secretion in β-cells during fasting 102 . However, many genes/proteins related to lung disease including cancer is highly interacting with SARS-CoV-2 infections, since the patients suffer from the major complexities when the virus infects the lung. The idiopathic pulmonary fibrosis (IPF) is treated as one of the most crucial and serious risk factors of COVID-19 103 , since the COVID-19 positive patients have a greater chance for being enhanced with the IPF which creates numerous complications and leads a high risk to recover from COVID-19 104, 105 . The TLR2 is highly responsive in immune-enhancing activity 106 and the Type 2 lung inflammation is associated with the PAG1 gene expression 107 .

The multivariate survival analysis for lung cancer patients is based on low and high expressions of hub-DEGs significantly differentiated the survival curves (Fig. 7b) , which indicates that the lung cancer is significantly influenced by the hub-DEGs of SARS-CoV-2 infection. Also, the patients with the lung cancers belong to the high risk of mortality from COVID-19 infection. The above discussion indicates that the proposed genomic biomarkers responsible for SARS-CoV-2 infection are also associated with various comorbidities including diabetes, lung diseases, and respiratory disease and immune systems. Therefore, covid-19 patients usually suffer from multiple complexities and reach to the severe condition that has complex comorbidities [108] [109] [110] .

To explore effective drugs for the treatments against SARS-CoV-2 infections with comorbidities, we considered the proposed human genomic biomarkers guided 10 hub-proteins (SNRPD2, ZFP36, NEDD9, KLF6, USP53, IGF2, TLR2, PAG1, GUCY1A2, and CXCL2) and 5 key TFs proteins (FOXC1, GATA2, SRF, FOXL1, and YY1) as the drug target receptor proteins and performed their docking analysis with the SARS-CoV-2 3CL protease-guided top ranked 90 FDA approved repurposable drugs. Then we selected top ranked 7 drugs (Torin-2, Rapamycin, Radotinib, Ivermectin, Thiostrepton, Tacrolimus, and Daclatasvir) as the candidate drugs for the treatment against SARS-CoV-2 infection, where the first two drugs showed strong binding affinities with all the target proteins (Fig. 8b) . Among the identified candidate drugs, the Ivermectin and the Rapamycin were used to treat the COVID-19 affected patients although it has a lack of wide range of information about their activity against the SARS-CoV-2 virus 111 . Since Ivermectin has a potential antiviral activity, it has been used in the treatment of various virus infection including the SARS-CoV-2 treatment by dosing solely or with a combining other drugs 112, 113 . Moreover, many studies suggested to use the Ivermectin as a potential therapeutic for COVID-19 114, 115 . On the other hand, Rapamycin is widely used as inhibitor of protein synthesis and constrains the expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10 116 , therefore it has been also given for COVID-19 treatment 116, 117 . Rapamycin can also interact with the spike protein of the SARS-CoV-2 and work in mTOR pathway inhibitors [118] [119] [120] [121] . This result is indicating the consistency of therapeutic potentiality of the proposed hub proteins and TFs for the COVID-19 treatment. The remaining drugs were found as new potential drug candidates based on their binding affinity with the hub proteins and TFs. The Torin-2 is considered as a kinase inhibitor which worked in the PI3K-Akt/mTOR signaling pathway 117, 119, 122 , which supports our previous pathway analysis for the hub proteins. Radotinib (IY-5511) were being prescribed for the chronic myeloid leukaemia (CML) 123, 124 whereas Thiostrepton was used for acute kidney injury treatment 125 . The evidences show that the Tacrolimus has a positive inhibitory impact on the COVID-19 patients with comorbidities like kidney and liver transplantation 126, 127 . Moreover, we validated these seven candidate drugs against the state-of-the-art alternatives already published top-ranked 11 independent and 8 protonated receptors and found their strong binding affinities (Fig. 8c) , which indicates that the proposed drugs are effective against the state-of-the-arts alternatives SARS-CoV-2 infection causing independent receptor proteins also. Finally, we examined the stability of top-ranked three drugs (Torin-2, Rapamycin and Radotinib) by using 100 ns MD-based MM-PBSA simulations for two top ranked proposed (TLR2, USP53) and independent (IRF7, STAT1) receptors, and observed their stable performance according to the laws of physics 128, 129 . Therefore, the proposed candidate drugs might play the vital role for the treatment against different variants of SARS-CoV-2 infections with comorbidities since our proposed target proteins are also associated with several comorbidities. The present study emphasises the further wet lab experimental validation for both the proposed target proteins and candidate drugs.

The present study aims to explore genomic biomarkers (drug targets) for SARS-CoV-2 infections highlighting their functions, pathways, regulatory factors, associated comorbidities and candidate drugs. To achieve the goal, at first 109 DEGs between SARS-CoV-2 and control sample were detected from RNA-Seq profiles. The top ranked 10 hub-DEGs/proteins (TLR2, USP53, GUCY1A2, SNRPD2, NEDD9, IGF2, CXCL2, KLF6, PAG1 and ZFP36) were identified as genomic biomarkers by the PPI network analysis of DEGs with the NetworkAnalyst tool and STRING database. Gene-set enrichment analysis (GSEA) through the GO functional and KEGG pathway was then conducted to predict the associated functions and pathways of these genomic biomarkers. The gene regulatory network (GRN) analysis identified top ranked 5 TFs proteins (FOXC1, GATA2, SRF, FOXL1 and YY1) and 6 miRNAs (miR-107, miR-16-5p, miR-103a-3p, miR-27a-3p, miR-155-5p and miR-1-3p) as the transcriptional and post-transcriptional factors, respectively. The diseases versus genomic biomarkers interaction network analysis, survival analysis of lung cancer patients with genomic biomarkers and literature review showed that our www.nature.com/scientificreports/ proposed genomic biomarkers are associated with various types of comorbidities including diabetes, lung and heart diseases, respiratory disease and immune systems. Then we considered 10 hub-proteins (proposed genomic biomarkers) and 5 key TFs-proteins as the drug target receptor proteins to explore effective drugs by molecular docking analysis with the SARS-CoV-2 3CL protease-guided top 90 FDA approved anti-viral drugs. Then we selected top ranked 7 candidate drugs (Torin-2, Rapamycin, Radotinib, Ivermectin, Thiostrepton, Tacrolimus and Daclatasvir) with respect to our proposed 15 target proteins for the treatment against SARS-CoV-2 infection. Then we investigated the resistance of our proposed candidate drugs against the state-of-the-art alternatives of recently published top ranked 11 independent receptors for SARS-CoV-2 infections and observed that our proposed drugs are also effective against those independent receptors. Finally, we investigated the stability performance of top three drugs (Torin-2, Rapamycin and Radotinib) by using 100 ns MD-based MM-PBSA simulations for two top ranked proposed receptors (TLR2, USP53) and top two independent receptors (IRF7, STAT1), and observed their stable performance. In the context of already published host transcriptome-guided candidate drugs for covid-19, so far, no researchers yet investigated the resistance of their suggested drugs against the state-of-the-art alternatives independent receptors proposed by others computationally. In this study, we considered this issue. Thus, we may sate that this study is partially unique. As covid-19 is a new coronavirus disease, there has been little research on exploring globally effective drugs. In this regard, this research on coronavirus disease might open up new possibilities to explore globally more effective drugs computationally.

Data sources and descriptions. We used both original data and metadata associated with SARS-CoV-2

infections to reach the goal of this study as described below.

RNA-Seq count dataset to explore genomic biomarkers and drug target key receptor proteins associated with SARS-CoV-2 infection. This dataset was downloaded from the NCBI Gene Expression Omnibus (GEO) data repository with the accession number GSE150316. This dataset consisted of 88 samples generated from different organs including lung, heart, jejunum, liver, kidney, bowel, fat, skin, bone marrow and placenta, where 5 samples were COVID-19 negative (control). The count of each sample was generated on 59,091 transcripts. This dataset was first analyzed by Desai et al. 130 to investigate the temporal and spatial heterogeneity of host genome response to SARS-CoV-2 pulmonary infection. In our case, we considered only lung tissue samples to avoid the spatial heterogeneity problem from the dataset. Our analyzed original dataset consisted of 35 lung tissue samples infected with SARS-CoV-2 (case) and 5 control samples.

protease-guided top listed 90 drugs out of 3410 FDA approved antiviral drugs published by Beck et al. 50 as the meta drug agents to explore few top ranked host transcriptome-guided drugs against SARS-CoV-2 infections by molecular docking with our proposed receptor proteins. The 3D structures of 90 FDA-approved drugs (Supplementary Table S1 ) were downloaded from PubChem database 54 . To validate our proposed host transcriptomeguided repurposed drugs by molecular docking with the top listed receptor proteins that were published in different reputed journals, we reviewed 22 different articles infections 28-49 associated with SARS-CoV-2 infections and selected 11 top listed receptor proteins out of 193. Then their docking performance with our proposed drugs were investigated whether the drugs are keeping consistency with high binding affinities as in our proposed drug target hub-DEGs.

biology approaches were utilized in this study as described below:

genes (DEG) is one the most important tasks in this study. There are several methods for identification of DEGs from RNA-Seq profiles. Most of them are sensitive to outlying observations. There are a few robust approaches for identification of DEGs from RNA-Seq profiles. However, non-robust approaches are slightly better than robust approaches in absence of outliers, while the robust approaches are much better than the classical approaches in presence of outliers. Therefore, we considered edgeR 131 as a popular non-robust and DESeq2 132 as a popular robust approaches to take their advantages in our analyses, since few RNA-Seq counts are often contaminated by outliers due to several steps involves in the data generating process. However, normalization is a compulsory step for RNA-Seq data analysis. It removes systematic technical bias from the data and makes the samples comparable. The edgeR approach utilizes TMM (trimmed mean of M values) normalization, whereas the DESeq2 utilizes the median-of-ratios method. The edgeR method was formulated based on generalized linear model (GLM) of the negative binomial family. It assumes negative binomial (NB) distribution for the read counts and uses the empirical Bayes for squeezing the tag-wise dispersions toward common dispersion, whereas DESeq2 also considered GLM of the NB family and assumes NB distribution for the read counts and uses the empirical Bayes to shrink gene-wise dispersion estimates towards fitted values. The edgeR approach utilizes the likelihood ratio test (LRT) statistic to calculate the p-values and test the null hypothesis of no differential read counts between case and control groups, whereas the DESeq2 utilizes the Wald test statistic to calculate the p-values and test the null hypothesis of no differential read counts between case and control groups. The p-values of both the edgeR and the DESeq2 approaches are then adjusted for multiple testing using the procedure of Benjamini and Hochberg 133 . www.nature.com/scientificreports/ In this paper, we considered the gth gene (g = 1,2, …, 59,091) as a differentially expressed gene (DEG) between case and control groups if its adjusted p g -value < 0.05 along with |log 2 (aFC g )|> 1 by controlling the false discovery rate (FDR) at 5%, otherwise, it was considered as equally expressed gene (EEG). The gth gene was considered as upregulated or downregulated DEG if its adjusted p g -value < 0.05 along with log 2 (aFC g ) > 1 or log 2 (aFC g ) < − 1, respectively. Here aFC is the abbreviation of average fold change which is defined as aFC g = x g /y g (the fold change of x g with respect to y g ), where x g and y g are the averages of normalized counts of case and control groups with respect to gth gene, respectively. For example, a change from y g = 3 to x g = 9 produces aFA g = 3 which is referred to as a "threefold upregulated in average". Similarly, a change from y g = 9 to x g = 3 produces aFA g = 1/3 which is referred to as a "threefold downregulated in average". Let A UR and A DR were the upregulated and downregulated DEGs-sets respectively, detected by edgeR. Again, let B UR and B DR were the upregulated and down-regulated DEGs-sets respectively, detected by DESeq2. Then we defined upregulated gene-set as (A UR ∪ B UR ) and down-regulated as (A DR ∪ B DR ) by combining the results DEGs results of edgR and DESeq2. Let C was the set of contradictory upregulated and downregulated DEGs estimated by both edgeR and DESeq2. For example, if a DEG g ∈ A UR but g / ∈ B UR or g ∈ A DR but g / ∈ B DR , then the DEG 'g' was considered as a contradictory DEG. We removed this type of contradictory DEGs from further analysis. Then the final DEGs-set for further analysis was defined as where, upregulated DEGs-set was defined as and the downregulated DEGs-set was defined as Functional and pathway enrichment analysis of Hub-DEGs. Gene ontology (GO) functional and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment/annotation/over-representation analysis 134 is a widely used approach to determine the significantly annotated/enriched/over-represented functions/classes/terms (biological processes (BP), molecular functions (MF) and cellular components (CC)) and pathways by the identified DEGs/Hub-DEGs. The BP is a change or complex of changes during the granularity period of the cell that is mediated by one or more gene products for different biological objectives. The MFs are the biochemical activities of gene products. The CC is a place in a cell in which a gene product is active. KEGG pathway is a collection of experimentally validated pathway maps [135] [136] [137] representing our knowledge of the molecular interaction, reaction and relation networks for metabolism, cellular processes, genetic information processing, organismal systems, environmental information processing, human diseases and drug development. Let S i is the annotated gene-set corresponding to ith type of biological functions or pathways given in the database and M i is the number of genes in S i (i = 1, 2,…,r); N is the total number of annotated genes those construct the entire combine set

where S c i is the complement set of S i . Again, let n is the total number of DEGs of interest and k i is the number of DEGs belonging to the annotated gene-set S i . This problem is summarized by the following contingency table (Table 1) :

The probability of observing exactly k i DEGs in S i (ith functional/pathway annotated gene-set) out of n DEGs can be modeled by the hypergeometric distribution. Hence, the probability of observing k i or more genes in S i out of n DEGs can be calculated by the cumulative probability as follows

The subset of DEGs belonging to S i is said to be significantly enriched if its adjusted p-value (p i ) is less than 0.05 by controlling the FDR at 5%. The g:GOSt core, a free web tool for functional analyses (https:// biit. cs. ut. ee/ gprofi ler/ gost), embedded with the g:Profiler web server 138 utilizes the cumulative hypergeometric approach to calculate these p-values (p i' s) and their adjusted p-values for multiple testing using the procedure of Benjamini and Hochberg 133 . The g:Profiler is a regularly updated database for performing GO functional and KEGG pathway enrichment analysis. Therefore, in this paper, we performed functional and pathway enrichment analysis by using the g:GOSt tool entrenched in the g:Profiler web server to disclose the statistically significant GO terms of biological processes, molecular functions and cellular components and KEGG pathways for DEGs associated with the SARS-CoV-2 infections. are the physical magnetism of two or more protein molecules that occur due to biochemical reactions steered by hydrogen bonding, electrostatic forces and the hydrophobic effect. Generally, a protein cannot work without interaction with one or more other proteins. The PPI network contributes to the formation of larger protein complexes for performing a specific task 139 . It carries out many molecular functions and biological processes including protein function, cell-to-cell interactions, metabolic and developmental control, disease incidence, and therapy design. A PPI network is represented as an undirected graph, where nodes and edges indicate proteins and their interactions, respectively. A node having the largest number of significant interactions/connections/edges with other nodes is considered as the top ranked hub-protein. Therefore, the PPI network analyses of DEGs are now widely using to explore hub-DEGs/proteins. In this study, the PPI network of DEGs was constructed by using the NetworkAnalyst 140 with the STRING database 141 plagued in Cytoscape. A topological exploration based on dual-metric measurements degree (> 10) and betweenness were utilized to determine the highly representative DEGs/proteins those are also known as hub-DEGs/proteins.

A gene regulatory network (GRN) shows molecular regulators that interact with each other to control the gene expression levels of mRNA and proteins. Transcription factors (TFs) and microRNAs (miRNAs) are considered as the most important molecular regulators of genes. A transcription factor (TF) is a protein that binds to a specific DNA region (promoter/enhancer) and regulates gene expression by promoting or suppressing transcription. TFs are considered as the main players in GRN. A miRNA is a small single-stranded non-coding RNA molecule (containing about 22 nucleotides) that works in RNA silencing and post-transcriptional regulation of gene expression. There are up to 1600 TFs and 1900 miR-NAs in the human genome. A TFs and hub-DEGs/proteins interaction network is considered as an undirected graph, where nodes indicate TFs or hub-DEGs and edges represents interactions between TFs and hub-DEGs, respectively. A TF-node having the largest number of significant interactions/connections/edges with hub-DEGs nodes is considered as the top ranked hub-TF regulator of hub-DEGs. To explore hub-TFs of hub-DEGs, we contracted the interaction network between TFs and hub-DEGs by using the NetworkAnalyst tool 140 based on JASPAR database 142 . Similarly, miRNA and hub-DEGs interaction network was constructed through the Net-workAnalyst based on TarBase V8.0 143 database to identify the key regulatory miRNAs for hub-DEGs. These key regulatory biomolecules were selected based on the highest topological matrices (degree of connectivity and betweenness) applied on the interaction network.

To investigate the association of hub-DEGs with other diseases, we performed diseases versus hub-DEGs interaction network analysis by using the NetworkAnalyst tool 140 based on DisGeNET 144 database. We also performed survival analysis based on the expression of hub-DEGs with lung cancer patients by using Kaplan-Meier (KM) plotter 145 to investigate the association of hub-DEGs with lung cancer, since SARS-CoV-2 samples were collected from lung tissue and also it affects the lung mostly. The KM plotter utilizes the log rank statistic to test the significance of association.

Drug repurposing by molecular docking study. To propose in-silico validated efficient FDA approved repurposed drugs for the treatment of SARS-CoV-2 infections, we employed molecular docking between the target receptor proteins and drug agents. We considered our proposed hub-DEGs based hub-proteins and associated TFs proteins as the drug target receptor proteins and SARS-CoV-2 transcriptome-guided top listed 90 drugs out of 3410 FDA approved antiviral drugs published by Beck et.al. 2020 50 as drug agents or ligands for docking analysis. The molecular docking study requires 3-Dimensional (3D) structures of both receptor proteins and candidate drugs. We downloaded the 3D structure of all targeted receptor proteins from Protein Data Bank (PDB) 51 and SWISS-MODEL 52 , a homology modeling based database. The 3D structures of our selected 90 drug agents (Supplementary Table S1 ) were downloaded from PubChem database 54 . The 3D structure of the target proteins was visualized using Discovery Studio Visualizer 2019 146 and the water molecules, co-crystal ligands which were bound to the protein were removed. Further, the protein was prepared using USCF Chimera and Autodock vina 147 in PyRx open source software by adding charges and minimizing the energy of the protein and subsequently converting it to pdbqt format [147] [148] [149] . The exhaustiveness parameter was set to 8. The Protein-Ligand Interaction Profiler (PLIP) web service 150 and PyMol 151 were used to analyze the docked complexes for surface complexes, types and distances of non-covalent bonds. Let A ij denotes the binding affinity between ith target protein (i = 1, 2, … , m) and jth drug agent (j = 1, 2, … , n). Then target proteins are ordered according to the descending order of row sums n j=1 A ij , j = 1,2, … , m, and drug agents are ordered according to the descending order of column sums m i=1 A ij , j = 1,2, … , n, to select the top ranking few drug agents as the candidate drugs. The average binding affinity score less than or equal to − 8.0 was considered as the better drug selection criterion against the receptor proteins. Then we validated the proposed repurposed drugs by molecular docking with the top listed receptor proteins associated with SARS-CoV-2 infections that were obtained by the literature review. To select the top listed receptor proteins associated with SARS-CoV-2 infections, we reviewed 22 recently published articles and selected the top listed 11 receptor proteins. Molecular dynamic (MD) simulations. MD simulations were carried out by using YASARA Dynamics software 152 , and the AMBER14 force field 153 to study the dynamic behavior of the top-ranked protein-ligand complexes. A total of six different systems were used to run MD simulation. The systems included top three hits, TLR2_Torin-2, TLR2_Rapamycin, USP53_Radotinib complexes corresponding to our proposed receptors and another three hits, IRF7_Torin-2, STAT1_Rapamycin, STAT1_Radotinib complexes from top listed independent receptors. Before simulation, the target-drug complex's hydrogen bonding network was optimized and www.nature.com/scientificreports/ solvated by a TIP3P 154 water model in a simulation cell. Periodic boundary conditions were maintained with a solvent density of 0.997 g L −1 . Titratable amino acids in the protein complex were subjected to pKa calculation during solvation. The initial energy minimization process of each simulation system, consisting of 41,645 ± 10, 41,645 ± 10, 95,924, 105,924 ± 10, 105,924 ± 10 and 85,924 atoms for TLR2_Torin-2, TLR2_Rapamycin, USP53_ Radotinib, STAT1_Rapamycin, STAT1_Radotinib and IRF7_Torin-2 complexes was performed by a simulated annealing method respectively, using the steepest gradient approach (5000 cycles). Each simulation was run with a multiple time step algorithm 155 , using a time-step interval of 2.50 fs under physiological conditions (298 K, pH 7.4, 0.9% NaCl) 156 . All bond lengths were constrained using the linear constraint solver (LINCS) 157 algorithm, and SETTLE 158 was used for water molecules. Long-range electrostatic interactions were described by the PME 159 methods, and, finally, 100 ns MD simulation was accomplished at Berendsen thermostat 160 and constant pressure. The trajectories were recorded every 250 ps for further analysis, and subsequent analysis was implemented by default script of YASARA 161 macro and SciDAVis free software available at http:// scida vis. sourc eforge. net/. All snapshots were then subjected to YASARA software's MM-PBSA (MM-Poisson-Boltzmann surface area) binding free energy calculation using the formula below 162 ,

Here, MM-PBSA binding energy was calculated using YASARA built-in macros using AMBER 14 as a force field, with larger positive energies indicating better binding 163 . The PBSA is one of the most appealing solvation systems used in computer-aided drug design techniques to determine binding energy of protein-drug complexes 164, 165 .

COVID-19) during pregnancy: prevalence of seroconversion, effect on maternal and perinatal outcomes and risk of vertical transmission

WHO | Summary of probable SARS cases with onset of illness from 1

The severe acute respiratory syndrome

The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: An analysis of all 1755 patients

Critically ill patients with severe acute respiratory syndrome

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO-China Jt. Mission Coronavirus Dis

WHO declares COVID-19 a pandemic

Emerging coronaviruses: Genome structure, replication, and pathogenesis

A novel coronavirus from patients with pneumonia in China

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

A new coronavirus associated with human respiratory disease in China

The 2019-new coronavirus epidemic: Evidence for virus evolution

Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)

Treatments and vaccines for COVID-19 | European Medicines Agency

Dissecting the molecular mechanisms of neurodegenerative diseases through network biology

Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer's disease

Drug targeting and biomarkers in head and neck cancers: insights from systems biology analyses

A robust approach for identification of cancer biomarkers and candidate drugs

Network-based computational approach to identify delineating common cell pathways influencing type 2 diabetes and diseases of bone and joints

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors

Natural-like products as potential SARS-CoV-2 Mpro inhibitors: In-silico drug discovery

In silico evaluation of prospective anti-COVID-19 drug candidates as potential SARS-CoV-2 main protease inhibitors

In silico mining of terpenes from red-sea invertebrates for SARS-CoV-2 main protease (Mpro) inhibitors

Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study

Diseasome and comorbidities complexities of SARS-CoV-2 infection with common malignant diseases

Network-based identification genetic effect of SARS-CoV-2 infections to idiopathic pulmonary fibrosis (IPF) patients

Gene expression profiling of SARS-CoV-2 infections reveal distinct primary lung cell and systemic immune infection responses that identify pathways relevant in COVID-19 disease

Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

In silico prediction of molecular targets of astragaloside IV for alleviation of COVID-19 hyperinflammation by systems network pharmacology and bioinformatic gene expression analysis

Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19

A lung transcriptomic analysis for exploring host response in COVID-19

Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19

CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients

Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking

Identification of key genes and pathways in SARS-COV-2 infection using bioinformatics analysis

Identification of potential key genes for SARS-CoV-2 infected human bronchial organoids based on bioinformatics analysis

Identification of common key genes and pathways between Covid-19 and lung cancer by using protein-protein interaction network analysis

Identication of key genes and pathways in the hPSC-derived lungs infected by the SARS-CoV-2

Identification of novel SARS-CoV-2 drug targets by host micrornas and transcription factors co-regulatory interaction network analysis

Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis

Identification of Hub genes associated with infection of three lung cell lines by SARS-CoV-2 with integrated bioinformatics analysis

Identification of biological correlates associated with respiratory failure in COVID-19

Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods

Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective

Identifying potential drug targets and candidate drugs for COVID-19: Biological networks and structural modeling approaches

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

The protein data bank

SWISS-MODEL: Homology modelling of protein structures and complexes

UniProt: a worldwide hub of protein knowledge The UniProt Consortium

PubChem 2019 update: Improved access to chemical data

H++: A server for estimating pKas and adding missing hydrogens to macromolecules

Hypothesis of COVID-19 therapy with sildenafil

Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury

Small molecule therapeutics for COVID-19: Repurposing of inhaled furosemide

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The COVID-19 cytokine storm; What we know so far

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial

Why COVID-19 is less frequent and severe in children: a narrative review

T cell-mediated immune response to respiratory coronaviruses

C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity

Immunometabolic status of covid-19 cancer patients

Role of DCP1-DCP2 complex regulated by viral and host microRNAs in DNA virus infection

Legionnaires Disease Signs and Symptoms | Legionella | CDC

Identifying common baseline clinical features of COVID-19: a scoping review

Pulmonary manifestations of Kaposi's sarcoma

Critical role of PI3k/Akt/GSK3β in motoneuron specification from human neural stem cells in response to FGF2 and EGF

PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation

Proteoglycans in cancer biology, tumour microenvironment and angiogenesis

FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization

Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics

GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer

Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1

Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: Big data mining and genomewide systems identification

Coordinated regulation of cell survival and cell cycle pathways by DDR2-dependent SRF transcription factor in cardiac fibroblasts

Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer

Gene expression profiling of gastric cancer

Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines

Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: Insights from systems biology analysis

The regulatory role of miR-107 in Coxsackie B3 virus replication

Evaluation of serum paired microRNA ratios for differential diagnosis of non-small cell lung cancer and benign pulmonary diseases

Circulating miR-103a-3p contributes to angiotensin II-induced renal inflammation and fibrosis via a SNRK/NF-κB/ p65 regulatory axis

MicroRNA-27a-3p directly targets FosB to regulate cell proliferation, apoptosis, and inflammation responses in immunoglobulin a nephropathy

Hsa-miR-155-5p up-regulation in breast cancer and its relevance for treatment with Poly[ADP-Ribose] polymerase 1 (PARP-1) inhibitors. Front

An in-silico approach to study the possible interactions of miRNA between human and SARS-CoV2

Identification of 13 key genes correlated with progression and prognosis in hepatocellular carcinoma by weighted gene co-expression network analysis

The predicted key molecules, functions, and pathways that bridge mild cognitive impairment (MCI) and Alzheimer's disease (AD)

MicroRNA-423 drug resistance and proliferation of breast cancer cells by targeting ZFP36

The mRNA-binding protein TTP/ZFP36 in hepatocarcinogenesis and hepatocellular carcinoma. Cancers (Basel)

Positive expression of NEDD9 in head and neck cancer is related to better survival period

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis

Long noncoding RNA PROX1-AS1 promoted ovarian cancer cell proliferation and metastasis by suppressing KLF6

KLF6 contributes to myeloid cell plasticity in the pathogenesis of intestinal inflammation

Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants

New paradigms of USP53 disease: Normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin

Integrin and autocrine IGF2-pathways control fasting insulin secretion in β-cells

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Viral infection increases the risk of idiopathic pulmonary fibrosis: A meta-analysis

Understanding of COVID-19 based on current evidence

Immune-enhancing activity of aqueous extracts from Artemisia rupestris L. via MAPK and NF-kB pathways of TLR4/TLR2 downstream in dendritic cells

PAG1 limits allergen-induced type 2 inflammation in the murine lung

Comorbidity and its impact on patients with COVID-19. SN Compr

The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Ivermectin in COVID-19: What do we know

Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen

Ivermectin: potential candidate for the treatment of Covid 19

Old and re-purposed drugs for the treatment of COVID-19

A review on current repurposing drugs for the treatment of COVID-19: Reality and challenges. SN Compr

Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19

mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19

Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: A novel binding site

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

Assessment of Evidence for COVID-19-Related Treatments

Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

Tyrosine kinase inhibitor dosing patterns in elderly patients with chronic myeloid leukemia

Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia

Glycogen synthase kinase-3β inhibits tubular regeneration in acute kidney injury by a FoxM1-dependent mechanism

Kidney transplantation in the times of covid-19-A literature review

Evolución clínica en un receptor de trasplante de hígado con la COVID-19: ¿Un efecto benéfico del tacrolimus?

Theoretical nuclear physics

Mechanistic and structural analysis of a family 31 α-glycosidase and its glycosyl-enzyme intermediate

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

edgeR: A bioconductor package for differential expression analysis of digital gene expression data

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Controlling the false discovery rate: A practical and powerful approach to multiple testing

GO::TermFinder-open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes INTRODUCTION: MOTIVATION AND DESIGN

New perspectives on genomes, pathways, diseases and drugs

KEGG as a reference resource for gene and protein annotation

Kyoto encyclopedia of genes and genomes

Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update)

History of protein-protein interactions: From egg-white to complex networks

NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data

The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible

Update of the open-access database of transcription factor binding profiles and its web framework

DIANA-TarBase v8: A decade-long collection of experimentally supported miRNA-gene interactions

The DisGeNET knowledge platform for disease genomics: 2019 update

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

UCSF Chimera-A visualization system for exploratory research and analysis

Small-molecule library screening by docking with PyRx

PLIP: Fully automated protein-ligand interaction profiler

PyMOL User's Guide

Lipid14: The amber lipid force field

Comparison of simple potential functions for simulating liquid water

New ways to boost molecular dynamics simulations

Fast empirical pKa prediction by Ewald summation

LINCS: A linear constraint solver for molecular simulations

An analytical version of the SHAKE and RATTLE algorithm for rigid water models

A smooth particle mesh Ewald method

Molecular dynamics with coupling to an external bath

Increasing the precision of comparative models with YASARA NOVA-A self-parameterizing force field

Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors

Computational investigation of curcumin, a natural polyphenol that inhibits the destabilization and the aggregation of human SOD1 mutant (Ala4Val)

In silico-based vaccine design against Ebola virus glycoprotein

Mechanism of microRNA-target interaction: Molecular dynamics simulations and thermodynamics analysis

We are very much grateful and thankful to all reviewers for their valuable comments that help us to improve the manuscript. We would like to acknowledge the MST (PID: 489-ID, 2020-2021) and BANBEIS (PID: MS20191106, 2020-2021) research project, Govt. of Bangladesh for supporting this research work.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-08073-8.Correspondence and requests for materials should be addressed to M.N.H.M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.